Updated on 13 May 2013
Our weakness is that we have not been able to do the high level of product development. It is still an under-developed and under-utilized area of the biotech sector. However, there is a lot of scope for the growth. With the availability of a national knowledge network, communicating and computing capabilities have enhanced tremendously.
The progress of programs such as Open Source Drug Discovery (OSDD) has served as an example where we can take lead in new discoveries. Unlike molecular biology, that took 20 years to reach to the level of product development, genomics has the availability of cutting-edge technologies and we can certainly achieve lot more than we think we can. With these technologies in our kitty, and along with efficient and capable manpower, we can do large scale discoveries. The connection between genomics and medicine is developing at a rapid pace for the first time. This is the area where I have huge expectations and see a bright future.
Actually, India can beat the best of the world in the field of predictive medicine, if we start making research headway in the right direction. So far the efforts have been lacking. Industry must come out of its conventional mode of thinking and researching. The use of latest authenticated technologies is a must and above all the benefit to the masses must be given due consideration whenever research is initiated.
As a person, when I look at a decade back, I feel that full scale exploitation of genomics could bring the change. Ten years down the lane, it has become a reality. So I am a satisfied person in that regard. What is now required is to focus on novel emerging areas. We should start now with extensive thrust on the areas such as biosensors and synthetic biology. India has to emerge as a leader in the future, and I have no doubt that she will succeed.